Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model

Fig. 1

Regular physical activity was associated with improved outcomes in HCC patients receiving combined therapy. In a cohort of patients with unresectable or advanced HCC treated with lenvatinib plus anti-PD-1 antibody combination, regular physical activity was associated with an improved overall survival (A), progression-free survival (B), and high rate of objective response (C). * P < 0.05, ** P < 0.01, *** P < 0.001. HCC hepatocellular carcinoma, OR objective response

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us